NEW YORK, April 1 Reportlinker.com announces that a new market research report is available in its catalogue:
The Cardiovascular Market Outlook to 2014: Competitive landscape, global market analysis and pipeline analysis
Advertisement
http://www.reportlinker.com/p0185306/The-Cardiovascular-Market-Outlook-to-2014-Competitive-landscape-global-market-analysis-and-pipeline-analysis.html
Advertisement
The Cardiovascular Market Outlook to 2014 provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands within each indication, in order to enable the reader to identify growth brands, key drug classes and leading players through 2014.
The cardiovascular market may be segmented into numerous subcategories, including antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents. While established treatments are currently available for each of these therapeutic subcategories, these markets are large and significant unmet medical needs still exists. Among the various cardiovascular indications, dyslipidemia had the highest prevalence in 2008, with over 300m people affected by the condition.
The global cardiovascular market is quite dynamic and has remained a leading therapy area in the global pharmaceutical market. Although the seven major markets (7MM) have captured a significant market share of the global cardiovascular market sales, these countries have recorded a strong Y-o-Y decline in 2008. The US continued to be a dominant market but registered a Y-o-Y decline in 2008, which was mainly attributed to increasing generic presence and market maturity in several key therapeutic categories.
Key features of this report
-- Epidemiological analysis and forecast prevalence of the major cardiovascular indications such as hypertension, dyslipidemia and stroke over the period 2008-14.
-- Forecasts and analysis of the major products in the cardiovascular market over the period 2008-14 spread across the major indications and classes of treatments.
-- Overview of key events in the global cardiovascular market that have impacted treatment trends and sales potential across the major cardiovascular indications.
-- Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.
Scope of this report
-- Quantify patient potential, assess treatment trends and sales patterns across the major cardiovascular disorder indications in the US, Japan and top 5 EU markets.
-- Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of the major classes such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents.
-- Compare the franchises of top pharmaceutical marketers across major indications, and evaluate how market share of leading companies, such as Pfizer, Sanofi-Aventis, Novartis, Merck, BMS and AstraZeneca will change over the next 5 years.
-- Quick and comprehensive understanding of how recent events are affecting the performance of major products, and how leading players are confronting competitive challenges in the cardiovascular marketplace.
Key questions answered
-- What will be the major growth indications and the accompanying growth drivers in the cardiovascular arena over the period 2008-14?
-- What are the current trends within the major therapy areas such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents across the seven major markets?
-- How have recent launches from companies such as Pfizer, Sanofi-Aventis, Novartis, Merck, BMS and AstraZeneca performed in the market place?
-- What are the most promising compounds currently in clinical development for major cardiovascular indications, and what is the forecast commercial potential of these products through 2014?
Companies mentioned
AstraZeneca , Bristol-Myers Squibb (BMS) , Merck & Co. , Novartis , Pfizer , Sanofi-Aventis
Table of Contents
The Cardiovascular Market Outlook to 2014
Executive summary 12
Overview and epidemiology of cardiovascular disorders 12
Global market analysis 12
Pipeline analysis 13
Competitive landscape 14
Scope and methodology 16
Scope 16
Methodology 17
Chapter 1 Overview and epidemiology of cardiovascular disorders 20
Summary 20
Introduction 20
Predisposing factors 21
Risk factors 24
Hypertension 24
Diagnosis, treatment and management 25
Epidemiology 27
Forecast epidemiology 28
Dyslipidemia 29
Diagnosis, treatment and management 30
Epidemiology 33
Forecast epidemiology 34
Cardiovascular diseases 35
Arteriosclerosis/atherosclerosis 35
Thrombosis 35
Cardiac arrhythmias 35
Myocardial infarction (MI) 36
Acute coronary syndrome (ACS) 36
Congestive heart failure (CHF) 36
Coronary artery disease (CAD) 36
Peripheral artery disease (PAD) 36
Pulmonary hypertension 36
Angina pectoris 37
Stroke 37
Epidemiology 38
Forecast epidemiology 39
Chapter 2 Global market analysis 42
Summary 42
Introduction 43
Market analysis by country 44
Key events in the cardiovascular market 48
Wider indications for Crestor 48
Evolving dynamics of the cholesterol market - patent expirations but an increasing patient base 49
Heightened interest in the HDL cholesterol market 49
ARBs a growing hypertension drug class 49
Tekturna/Rasilez uptake slower than expected 50
Micardis label expansion in the EU 50
Market analysis by drug class 51
Antihypertensive treatments 52
Introduction 52
Different classes of antihypertensives 53
Leading treatment brands by drug class 54
Key brands analysis 56
Diovan/Co-Diovan 56
Norvasc 57
Cozaar 58
Trends in generics usage 59
Antidyslipidemics 60
Introduction 60
Antidyslipidemics drug classes 61
Leading treatment brands by drug class 62
Key brands analysis 64
Lipitor 64
Crestor 66
Trends in generics usage 70
Antithrombotics treatments 71
Introduction 71
Antithrombotics drug classes 72
Leading treatment brands by drug class 73
Key brands analysis 74
Plavix 74
Lovenox 77
Trends in generics usage 78
Other cardiovascular agents 79
Introduction 79
Leading brands by drug class 79
Key brands analysis 80
Tracleer 80
Trends in generics usage 82
Cardiac therapies 82
Introduction 82
Market analysis by drug class 83
Leading treatment brands by drug class 84
Trends in generics usage 85
Cardiovascular sales forecast to 2014 86
Leading brands dynamics 87
Chapter 3 Pipeline analysis 90
Summary 90
Introduction 91
Key events in the cardiovascular market 91
BMS/Pfizer's apixaban is on track for EU regulatory submission in venous
thromboembolism (VTE) 91
Plavix receives a US warning on omeprazole interaction 91
Mipomersen from Genzyme may become a novel option for high cholesterol 92
New treatments drive robust growth of the anticoagulants class 92
Persistent interest in drugs which increase HDL cholesterol levels 93
Valturna remains the first hypertension combination drug to receive US approval 94
NICE drafts guidelines on hypertension treatment in pregnancy 95
Cardiovascular pipeline 96
Leading drugs in development 98
Profiles of key pipeline products 99
Recently approved/launched drugs 99
Pradaxa/Rendix (dabigatran) - Boehringer Ingelheim 99
Multaq (dronedarone) - Sanofi-Aventis 100
Xarelto (rivaroxaban) - Bayer Schering/J&J 102
Effient/Efient (prasugrel) - Eli Lilly/Daiichi Sankyo 104
Recently filed/pre-registration compounds 106
Apixaban - Bristol-Myers Squibb (BMS)/Pfizer 106
Certriad (rosuvastatin/ fenofibric acid) - AstraZeneca/Abbott 107
Brilinta (ticagrelor/AZD6140) - AstraZeneca 108
Phase II/III compounds 110
LCZ696 - Novartis 110
SCH 530348 - Merck 111
Edoxaban (DU-176b) - Daiichi Sankyo 113
Tyrisa/darapladib - GSK 114
Betrixaban - Portola/Merck 115
Pipeline forecast 117
Chapter 4 Competitive landscape 120
Summary 120
Introduction 121
Competitive positioning of top players in the cardiovascular market 121
Detailed analysis of leading cardiovascular players 123
Pfizer 123
Overview 123
Regional sales distribution 124
Sales focus by drug class 124
Marketed product portfolio 126
R&D pipeline analysis 128
Strategic and growth analysis 129
Sanofi-Aventis 131
Overview 131
Regional sales distribution 131
Sales focus by drug class 132
Marketed product portfolio 135
R&D pipeline analysis 137
Strategic and growth analysis 138
Novartis 139
Overview 139
Regional sales distribution 140
Sales focus by drug class 140
Marketed product portfolio 142
R&D pipeline analysis 144
Strategic and growth analysis 145
Merck & Co 146
Overview 146
Regional sales distribution 147
Sales focus by drug class 148
Marketed product portfolio 150
R&D pipeline analysis 151
Strategic and growth analysis 153
Bristol-Myers Squibb (BMS) 154
Overview 154
Regional sales distribution 155
Sales focus by drug class 155
Marketed product portfolio 156
R&D pipeline analysis 158
Strategic and growth analysis 159
AstraZeneca 161
Overview 161
Regional sales distribution 161
Sales focus by drug class 162
Marketed product portfolio 163
R&D pipeline analysis 166
Strategic and growth analysis 167
Competitive positioning of top generic players in the cardiovascular market 168
Leading generic players by region 171
Appendix 173
IMS Data 173
Glossary 175
Index 179
List of Figures
Figure 1.1: Cardiovascular disease etiology 23
Figure 1.2: Cardiovascular risk factors 24
Figure 1.3: Definition and classification of hypertension 25
Figure 1.4: Hypertension - treatment options 26
Figure 1.5: Types of lipoproteins 30
Figure 1.6: Interpretation of blood lipid levels 31
Figure 1.7: LDL levels and therapy patterns 32
Figure 2.8: Relative positions of the 7MM in the global cardiovascular market, 2008 44
Figure 3.9: Cardiovascular pipeline by indication and stage of development, 2009 96
Figure 3.10: Leading recently marketed and late-stage R&D products in the cardiovascular market, 2009 98
Figure 4.11: Competitive dynamics of the top 10 cardiovascular players over the period 2007-08 122
Figure 4.12: Pfizer's top 10 cardiovascular drug classes by sales ($m), 2008 125
Figure 4.13: Sanofi-Aventis' top 10 cardiovascular drug classes by sales ($m), 2008 133
Figure 4.14: Novartis' top 10 cardiovascular drug classes by sales ($m), 2008 141
Figure 4.15: Merck's top 10 cardiovascular drug classes by sales ($m), 2008 148
Figure 4.16: BMS' top 10 cardiovascular drug classes by sales ($m), 2008 156
Figure 4.17: AstraZeneca's top 10 cardiovascular drug classes by sales ($m), 2008 163
Figure 4.18: Competitive positioning of the top 10 generic players in the global cardiovascular market, 2008 169
Figure 4.19: Relative positioning of the top 10 generic and branded players in the global cardiovascular market, 2008 171
List of Tables
Table 1.1: Estimated prevalence of cardiovascular disorders across seven major markets (in thousands), 2008 21
Table 1.2: Estimated prevalence of hypertension across the seven major markets (in thousands), 2008 27
Table 1.3: Forecast epidemiology of hypertension across the seven major markets (in thousands), 2008-14 28
Table 1.4: Estimated prevalence of dyslipidemia across the seven major markets (in thousands), 2008 33
Table 1.5: Forecast epidemiology of dyslipidemia across the seven major markets (in thousands), 2008-14 34
Table 1.6: Estimated prevalence of stroke across the seven major markets (in thousands), 2008 38
Table 1.7: Forecast epidemiology of stroke across the seven major markets (in thousands), 2008- 14 39
Table 2.8: US cardiovascular drug sales by ATC3 class, 2008 US$ millions 45
Table 2.9: Japan cardiovascular drug sales by ATC3 class, 2008 US$ millions 45
Table 2.10: France cardiovascular drug sales by ATC3 class, 2008 US$ millions 46
Table 2.11: Germany cardiovascular drug sales by ATC3 class, 2008 US$ millions 46
Table 2.12: Italy cardiovascular drug sales by ATC3 class, 2008 US$ millions 47
Table 2.13: Spain cardiovascular drug sales by ATC3 class, 2008 US$ millions 47
Table 2.14: UK cardiovascular drug sales by ATC3 class, 2008 US$ millions 48
Table 2.15: The global cardiovascular market by therapeutic segments ($m), 2007-2008 51
Table 2.16: Leading antihypertensive brands in the global cardiovascular market, 2008 55
Table 2.17: Comparison of generics and branded drugs in the global antihypertensive market, 2008 60
Table 2.18: Leading antidyslipidemic treatments in the global cardiovascular market, 2008 63
Table 2.19: Comparison of generics and branded drugs in the global antidyslipidemic market, 2008 71
Table 2.20: Leading antithrombotics treatments in the global cardiovascular market, 2008 74
Table 2.21: Comparison of generics and branded drugs in the global antithrombotics market, 2008 79
Table 2.22: Other cardiovascular treatments in the global cardiovascular market 2008 80
Table 2.23: Comparison of generics and branded drugs in the other cardiovascular agents market, 2008 82
Table 2.24: Leading cardiac therapies in the global cardiovascular market 2008 84
Table 2.25: Comparison of generics and branded drugs in the global cardiac therapies market, 2008 85
Table 2.26: Cardiovascular market sales forecast by therapeutic segments ($m), 2008-14 86
Table 2.27: Leading brands in the global cardiovascular market ($m), 2008 87
Table 2.28: Top 10 brands of the cardiovascular market, sales forecast 2008-14 88
Table 3.29: An overview of Pradaxa 99
Table 3.30: An overview of Multaq 101
Table 3.31: An overview of Xarelto 103
Table 3.32: An overview of Effient 105
Table 3.33: An overview of apixaban 106
Table 3.34: An overview of Certriad 108
Table 3.35: An overview of Brilinta 109
Table 3.36: An overview of LCZ696 110
Table 3.37: An overview of SCH530348 111
Table 3.38: An overview of edoxaban (DU-176b) 113
Table 3.39: An overview of Tyrisa 114
Table 3.40: An overview of betrixaban 116
Table 3.41: Key pipeline and recently approved/launched cardiovascular products sales forecast, 2008-14 118
Table 4.42: Leading players of the cardiovascular market based on prescription sales, 2008 123
Table 4.43: Regional sales distribution of Pfizer, 2008 124
Table 4.44: Pfizer's leading cardiovascular brands, 2008 126
Table 4.45: Pfizer's cardiovascular R&D portfolio, 2009 129
Table 4.46: Regional sales distribution of Sanofi-Aventis, 2008 132
Table 4.47: Sanofi-Aventis' leading cardiovascular brands, 2008 135
Table 4.48: Sanofi-Aventis' cardiovascular R&D portfolio, 2009 137
Table 4.49: Regional sales distribution of Novartis, 2008 140
Table 4.50: Novartis' leading cardiovascular brands, 2008 142
Table 4.51: Novartis' cardiovascular R&D portfolio, 2009 145
Table 4.52: Regional sales distribution of Merck, 2008 147
Table 4.53: Merck's leading cardiovascular brands, 2008 150
Table 4.54: Merck's cardiovascular R&D portfolio, 2009 152
Table 4.55: Regional sales distribution of BMS, 2008 155
Table 4.56: BMS' leading cardiovascular brands, 2008 157
Table 4.57: BMS' cardiovascular R&D portfolio, 2009 159
Table 4.58: Regional sales distribution of AstraZeneca, 2008 162
Table 4.59: AstraZeneca's leading cardiovascular brands, 2008 164
Table 4.60: AstraZeneca's cardiovascular R&D portfolio, 2009 166
Table 4.61: Leading generic players in global cardiovascular market, 2008 170
Table 4.62: Leading generic players by region, 2008 172
To order this report:
Cardiovascular Devices Industry: The Cardiovascular Market Outlook to 2014: Competitive landscape, global market analysis and pipeline analysis
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
